CA3049161C - Piperidine-2,6-dione derivatives and crohn's disease treating - Google Patents
Piperidine-2,6-dione derivatives and crohn's disease treating Download PDFInfo
- Publication number
- CA3049161C CA3049161C CA3049161A CA3049161A CA3049161C CA 3049161 C CA3049161 C CA 3049161C CA 3049161 A CA3049161 A CA 3049161A CA 3049161 A CA3049161 A CA 3049161A CA 3049161 C CA3049161 C CA 3049161C
- Authority
- CA
- Canada
- Prior art keywords
- pharmaceutically acceptable
- acceptable salts
- dione
- dioxopiperidin
- amino
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4891—Coated capsules; Multilayered drug free capsule shells
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201611041317 | 2016-11-24 | ||
| CN201611041317.5 | 2016-11-24 | ||
| PCT/CN2017/112669 WO2018095378A1 (zh) | 2016-11-24 | 2017-11-23 | 哌啶-2,6-二酮衍生物以及克罗恩氏病的治疗 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CA3049161A1 CA3049161A1 (en) | 2018-05-31 |
| CA3049161C true CA3049161C (en) | 2023-03-07 |
Family
ID=62194806
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3049161A Active CA3049161C (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-dione derivatives and crohn's disease treating |
| CA3045703A Active CA3045703C (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-dione derivatives and ulcerative colitis treating |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3045703A Active CA3045703C (en) | 2016-11-24 | 2017-11-23 | Piperidine-2,6-dione derivatives and ulcerative colitis treating |
Country Status (7)
| Country | Link |
|---|---|
| US (4) | US11485724B2 (enExample) |
| EP (2) | EP3546450A4 (enExample) |
| JP (2) | JP7143295B2 (enExample) |
| CN (2) | CN108101887A (enExample) |
| AU (2) | AU2017366514B2 (enExample) |
| CA (2) | CA3049161C (enExample) |
| WO (2) | WO2018095377A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2018095377A1 (zh) | 2016-11-24 | 2018-05-31 | 天津和美生物技术有限公司 | 哌啶-2,6-二酮衍生物以及溃疡性结肠炎的治疗 |
| CN108727319A (zh) * | 2018-09-05 | 2018-11-02 | 常州大学 | 一种3-硝基邻苯二甲酸酐的制备方法 |
| CN109293631B (zh) * | 2018-11-30 | 2020-05-08 | 常州制药厂有限公司 | 3-氨基-n-(2，6-二氧代-3-哌啶基)-邻苯二甲酰亚胺化合物的制备方法 |
| GB202002926D0 (en) * | 2020-02-28 | 2020-04-15 | Benevolentai Tech Limited | Compositions and uses thereof |
| CN111320604B (zh) * | 2020-04-22 | 2021-02-09 | 牡丹江医学院 | 一种治疗小儿口腔黏膜疾病的化合物、制备方法及其用途 |
| CN118370746A (zh) * | 2024-04-25 | 2024-07-23 | 江苏省中医院 | 马尿酸在制备溃疡性结肠炎治疗药物中的应用 |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2172474B1 (es) * | 2001-03-01 | 2004-01-16 | Fundacion Universitaria San Pa | Derivados de glutarimida como agentes terapeuticos. |
| EP1336602A1 (en) * | 2002-02-13 | 2003-08-20 | Giovanni Scaramuzzino | Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases |
| CN100488959C (zh) | 2003-03-27 | 2009-05-20 | 天津和美生物技术有限公司 | 水溶性的酞胺哌啶酮衍生物 |
| CA2808646C (en) * | 2003-09-17 | 2016-08-23 | The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services | Thalidomide analogs as tnf-alpha modulators |
| BRPI0607239A2 (pt) | 2005-01-25 | 2009-08-25 | Celgene Corp | usos de uma quantidade terapeuticamente ou profilaticamente eficaz de 4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol-1,3-d iona, de (3r)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, e de (3s)-4-amino-2-(3-metil-2,6-dioxopiperidin-3-il)-isoindol- 1,3-diona, ou um sal ou solvato farmaceuticamente aceitável das mesmas, composição farmacêutica, e, forma de dosagem unitária simples |
| CN100383139C (zh) * | 2005-04-07 | 2008-04-23 | 天津和美生物技术有限公司 | 可抑制细胞释放肿瘤坏死因子的哌啶-2，6-二酮衍生物 |
| CN1961876A (zh) * | 2005-11-08 | 2007-05-16 | 北京恩华医药研究院 | 邻苯二甲酰亚胺衍生物在制备抗新血管生成的药物中的用途 |
| ES2664872T3 (es) * | 2010-06-18 | 2018-04-23 | Taiho Pharmaceutical Co., Ltd | Moduladores PRPK-TPRKB y sus usos |
| EP2981262A1 (en) | 2013-04-02 | 2016-02-10 | Celgene Corporation | Methods and compositions using 4-amino-2-(2,6-dioxo-piperidine-3-yl)-isoindoline-1,3-dione for treatment and management of central nervous system cancers |
| WO2018095377A1 (zh) | 2016-11-24 | 2018-05-31 | 天津和美生物技术有限公司 | 哌啶-2,6-二酮衍生物以及溃疡性结肠炎的治疗 |
-
2017
- 2017-11-23 WO PCT/CN2017/112668 patent/WO2018095377A1/zh not_active Ceased
- 2017-11-23 EP EP17874499.1A patent/EP3546450A4/en active Pending
- 2017-11-23 US US16/464,224 patent/US11485724B2/en active Active
- 2017-11-23 CA CA3049161A patent/CA3049161C/en active Active
- 2017-11-23 AU AU2017366514A patent/AU2017366514B2/en active Active
- 2017-11-23 CA CA3045703A patent/CA3045703C/en active Active
- 2017-11-23 AU AU2017366515A patent/AU2017366515B2/en active Active
- 2017-11-23 JP JP2019528110A patent/JP7143295B2/ja active Active
- 2017-11-23 US US16/464,228 patent/US20220372013A2/en active Pending
- 2017-11-23 CN CN201711185728.6A patent/CN108101887A/zh active Pending
- 2017-11-23 EP EP17873820.9A patent/EP3546449A4/en active Pending
- 2017-11-23 WO PCT/CN2017/112669 patent/WO2018095378A1/zh not_active Ceased
- 2017-11-23 CN CN201711184758.5A patent/CN108101886A/zh active Pending
- 2017-11-23 JP JP2019528114A patent/JP7143296B2/ja active Active
-
2022
- 2022-06-03 US US17/832,518 patent/US11873287B2/en active Active
-
2023
- 2023-12-08 US US18/533,755 patent/US12331030B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| AU2017366514B2 (en) | 2021-01-21 |
| CA3045703C (en) | 2021-11-02 |
| US11873287B2 (en) | 2024-01-16 |
| JP2020500205A (ja) | 2020-01-09 |
| CA3049161A1 (en) | 2018-05-31 |
| CA3045703A1 (en) | 2018-05-31 |
| US12331030B2 (en) | 2025-06-17 |
| US20220372013A2 (en) | 2022-11-24 |
| JP2020500204A (ja) | 2020-01-09 |
| US20190352277A1 (en) | 2019-11-21 |
| CN108101886A (zh) | 2018-06-01 |
| AU2017366515A1 (en) | 2019-06-13 |
| WO2018095378A1 (zh) | 2018-05-31 |
| EP3546449A1 (en) | 2019-10-02 |
| EP3546449A4 (en) | 2020-06-10 |
| EP3546450A1 (en) | 2019-10-02 |
| US20220306600A1 (en) | 2022-09-29 |
| WO2018095377A1 (zh) | 2018-05-31 |
| US11485724B2 (en) | 2022-11-01 |
| AU2017366515B2 (en) | 2021-01-21 |
| AU2017366514A1 (en) | 2019-06-13 |
| JP7143296B2 (ja) | 2022-09-28 |
| JP7143295B2 (ja) | 2022-09-28 |
| US20240132466A1 (en) | 2024-04-25 |
| CN108101887A (zh) | 2018-06-01 |
| EP3546450A4 (en) | 2020-06-10 |
| US20190389835A1 (en) | 2019-12-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2017366515B2 (en) | Piperidine-2,6-diketone derivative and treatment for Crohn's disease | |
| CN111662281B (zh) | 水杨酸类小檗碱型生物碱季铵盐及其制备药物的用途 | |
| BR112016010515B1 (pt) | Uso de um composto derivado de glutarimida no tratamento de doenças eosinofílicas | |
| US20220288084A1 (en) | Nucleoside derivative for preventing and treating inflammation and application thereof | |
| WO2022194136A1 (zh) | 二苯烷类化合物及其制备方法、药物组合物和用途 | |
| WO2002060435A1 (fr) | Cryptotanshinone permettant de prevenir et d'attenuer la maladie d'alzheimer | |
| RU2456271C2 (ru) | Синтез и способы применения производных пироглутаминовой кислоты | |
| CN119528936B (zh) | 一种巴洛沙韦衍生物及其用途 | |
| WO2017074957A1 (en) | Oxysterols and hedgehog signaling | |
| WO2006007794A1 (en) | Cis-1,2-substituted stilbene derivates and the use thererof for manufacturing medicaments for treating medicaments for treating and/or preventing diabetes | |
| CN105237487B (zh) | 含川芎嗪基查尔酮芳氧烷酸类化合物、制备方法及其应用 | |
| US9193699B2 (en) | Apoptosis inducing compounds | |
| TW201831177A (zh) | 醯胺衍生物 | |
| CN110498761B (zh) | 乙酰金刚烷胺哌嗪(啶)类化合物作为脑神经保护剂应用 | |
| CN112245422A (zh) | 乙酰缬草素的新应用 | |
| CN106265677B (zh) | 一种防治溃疡性结肠炎的药物组合物及其应用 | |
| HK40107092A (en) | Dhodh inhibitors containing a carboxylic acid bioisostere | |
| CN106946851B (zh) | 一种用于预防和治疗肾结石的药物 | |
| CN106279164A (zh) | 新的5型磷酸二酯酶抑制剂及其应用 | |
| CN101811974A (zh) | 4-(3-(二甲氨基)丙氧基)-3,5-二甲氧基苯甲酸、其制法及医药用途 | |
| CN120757534A (zh) | 喹唑林类化合物及其用途 | |
| WO2024002112A1 (zh) | 一种治疗猫冠状或杯状病毒感染的方法 | |
| CN115504972A (zh) | 异恶唑类衍生物、其制备方法及其作为药物的用途 | |
| WO2019160926A1 (en) | Compounds comprising short-chain fatty acid moieties and compositions and methods thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20190523 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 7TH ANNIV.) - SMALL Year of fee payment: 7 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20241111 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20241111 |
|
| MPN | Maintenance fee for patent paid |
Free format text: FEE DESCRIPTION TEXT: MF (PATENT, 8TH ANNIV.) - SMALL Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20251110 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-4-4-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20251110 |